Anavex Life Sciences Corp (AVXL)

[bas2020]

At the meeting, when Dr. Missling commented about Anavex Plus not showing to be anymore beneficial than 2-73 alone, he seemed to indicate this was good news in that only one drug would need to be administered (i.e. less is better). Plus, donepezil is not well tolerated by 20% of patients, thus, avoiding the adverse side affects many exhibit with it. Therefore, I'd be surprised that they continue with the Plus patent, unless they just want to have it in their back pocket.